Global Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other 2017-2020: Non Invasive Game Changer / Lower Cost / Greater Accuracy - Research and Markets

DUBLIN, Mar 10, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides" report to their offering.

The Diagnostic, Monitoring and Screening Test opportunities are explored.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers.

What is the size of the huge screening opportunity? They are all listed in this extensive report.

Key Topics Covered:

1. Introduction and Market Definition
1.1 What is Liquid Biopsy?
1.2 The Sequincing Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 A Spending Perspective on Liquid Biopsy
1.5.1 An Historical Look at Clinical Testing

2. Market Overview
2.1 Players in a Dynamic Market
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10  Certification Body
2.2 Using Biopsies
2.2.1 Cancer
2.2.2 Precancerous conditions
2.2.3 Inflammatory conditions
2.3 Biopsy Sites
2.4 The Situation Today - Biopsy Analysis
2.5 Evidence of Cancer - Liquid Biopsy Technology
2.5.1 The Big Picture on Liquid Biopsy Technology
2.5.2 The Role of CTCs
2.5.2.1 Types of CTCs
2.5.2.2 CellSearch Detection- Ultimate Sensitivity
2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead
2.5.2.4 Maintrac Detection - The Microscope
2.5.2.5 Other Methods
2.5.3 ctDNA - Going Mainstream?
2.5.4 Exosomes and Micro Vesicles - New Kid on Block
2.6 Cancer Treatment Protocol Under Siege
2.6.1 Issues and Limitations to Liquid Biopsy Adoption
2.6.2 The Cancer Screening Market Opportunity
2.6.2.1 GRAIL - What Is It?
2.6.3 Cancer Management vs. Diagnosis
2.6.3.1 The Role of Risk Assessment
2.6.3.2 Managing Therapy
2.6.3.3 Monitoring Disease - What Is It?
2.6.4 Phases of Adoption - Looking Into The Future
2.6.5 The Promise of Liquid Biopsy
2.7 Structure of Industry Plays a Part
2.7.1 Hospital Testing Share
2.7.2 Economies of Scale
2.7.2.1 Hospital vs. Central Lab
2.7.3 Physician Office Lab's
2.7.4 Physician's and POCT
2.8 Profiles of Key Players
2.8.1 AdnaGen (now Qiagen)
2.8.2 Agena Bioscience
2.8.3 Angle plc
2.8.4 ApoCell
2.8.5 Biocept
2.8.6 BioFluidica
2.8.7 Bio-Rad Laboratories
2.8.8 Boreal Genomics
2.8.10 Chronix Biomedical
2.8.11 Clearbridge BioMedics
2.8.12 Cynvenio
2.8.13 Cytolumina Technologies Corp
2.8.14 CytoTrack
2.8.15 Diagnologix LLC
2.8.16 Epic Sciences
2.8.17 Exosome Diagnostics
2.8.18 Exosome Sciences
2.8.19 Fluidigm Corp
2.8.20 Fluxion Biosciences
2.8.21 Genomic Health
2.8.39 GRAIL
2.8.22 Guardant Health
2.8.23 HansaBiomed
2.8.23 Horizon Discovery
2.8.24 iCellate
2.8.25 Illumina
2.8.26 Inivata
2.8.27 Janssen Diagnostics
2.8.28 Molecular MD
2.8.29 Myriad Genetics
2.8.30 Natera
2.8.31 New Oncology
2.8.32 Personal Genome Diagnostics
2.8.33 RainDance Technologies
2.8.34 Rarecells SAS
2.8.35 Silicon Biosystems
2.8.36 Sysmex Inostics
2.8.37 SRI International
2.8.38 Trovagene

3. Market Trends
3.1 Factors Driving Growth
3.1.1 Non Invasive Game Changer
3.1.2 Lower Cost
3.1.3 Greater Accuracy.
3.1.4 Wide Range of Potential Uses
3.1.5 Aging Population
3.2 Factors Limiting Growth
3.2.1 Lower prices
3.2.2 Lack of Standards.
3.2.3 Protocol Resistance.
3.2.4 Initial Adoption Has No Cost Savings
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role.
3.4 Diagnostic Technology Development
3.4.1  Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 CGES Testing, A Brave New World
3.4.5 Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
4.2 Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy
4.3 ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy
4.4 Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study
4.5 Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen
4.6 Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test
4.7 Baylor, TGen Collaborate on Personalized Cancer Treatment Options
4.8 Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab
4.9 Broad Institute Lands $10M Gift to Study Cancer Drug Resistance
4.10 Biocept Q1 Revenues Rise With Test Volume Growth
4.11 CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers
4.12 New Oncology Closes Financing Round to Promote Genetic Testing from Blood
4.13 Cynvenio to present new clinical data
4.14 EKF, Angle Collaborate for Liquid Biopsy Development
4.15 Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer
4.16 AstraZeneca Initiates CDx Partnerships with Roche, Qiagen
4.17 Horizon, LGC Awarded Research Grant for Cancer Diagnostics
4.18 Merck Serono and Sysmex Inostics Announce Testing Center
4.19 Agena Bioscience Launches Smaller Format MassArray
4.20 Personal Genome Diagnostics Aims for FDA Clearance
4.21 HTG Molecular Diagnostics Files for IPO of up to $60M
4.22 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter
4.23 Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs
4.24 Inivata Raises $6.6M to Develop ctDNA Assays
4.25 Epic Sciences Raises $30M in Private Financing
4.26 New Release in Line of Liquid Biopsy CLIA Tests
4.27 Collaborators Publish Data on Resolution Bio Liquid Biopsy Test
4.27 Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field
4.28 FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test
4.29 DNA in blood can track cancer development, response in real time
4.30 Cynvenio Clinical Trial Supports Multi-Template Liquid Biopsy Sequencing
4.31 Startup AccuraGen to Tap China Liquid Biopsy Market With 61-Gene Assay
4.32 Sysmex Corporation and Clearbridge BioMedics to Jointly Develop New Liquid Biopsy System
4.33 MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States
4.34 GATC Biotech's Liquid Biopsy Testing Takes Cost Lead
4.35  Liquid Biotech USA, Inc. Announces Completion of  Clinical Study
4.36 Liquid biopsies more effective in some cases than tissue biopsies
4.37 Cancer Genetics, Inc. and ApoCell Announce Partnership for Rare Cell Capture and Detection
4.38 Exosome Diagnostics Launches Liquid Biopsy Test to Rule Out High-Grade Prostate Cancer
4.39 Liquid Biopsy Tests Partially Validated
4.40 FDA Approves Liquid Biopsy
4.41 Liquid Biopsy Predicts Colon Cancer Recurrence
4.42  WaveSense Receives CE-IVD Mark for Cell Enrichment Platform
4.43  For Liquid Biopsy, Size Matters
4.44 Liquid biopsy startup Freenome lands $5.5 million led by Andreessen Horowitz
4.45  Trovagene, USC Collaborate on Deployment of Urine-Based Liquid Biopsy Test
4.46  Circulogene liquid biopsy detects new tumor mass earlier than current imaging methods
4.47  Clinical Utility of Biocept's Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium
4.48  Trovagene to Focus More on Liquid Biopsy Testing Market
4.49  Pancreatic Cancer Gets Prognostic Tool from Liquid Biopsy
4.50  New Start-up to Work on Scalpel-free Liquid Biopsies
A researher at University of California, Berkeley, is launching a start-up called KarnaTeq to develop and market technology to increase the diagnostic power of scalpel-free biopsy.

5.  Country Market Sizes - North America

6. Country Markets - Europe

7. Country Markets - Asia Pacific

8. Country Markets - Latin America, Africa & The Middle East

9. Global Market Summary

10. Potential Market Opportunity Sizes
10.1 Cancer Screening by Country: Lung, Breast & Colorectal
10.2 Cancer Screening by Country: Prostate, Other Cancer & All Cancer
10.3 Potential Market Size - Cancer Diagnosis
10.4 Potential Market Size - Cancer Management

Appendices
I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint
II. FDA Approved Human Genetic Tests
III. FDA Approved Pharmacogenomics Tests

For more information about this report visit http://www.researchandmarkets.com/research/tw84rh/liquid_biopsy

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets